Pak J Med Sci
-
To understand the incidence and related risk factors of extrauterine growth retardation (EUGR) in preterm infants. ⋯ The incidence of EUGR in premature infants at discharge is relatively high. Strengthening perinatal health care for pregnant women, reducing the incidence of intrauterine growth retardation and preterm birth, giving intestinal feeding as soon as possible after birth, and actively participating in preventing and treating postnatal complications are effective ways to reduce the incidence of EUGR at discharge.
-
To compare the clinical effects of Osimertinib and Gefitinib in the treatment of non-small cell lung (NSCLC) complicated with epidermal growth factor receptor (EGFR) gene mutation. ⋯ The clinical effect of oxitinib in the treatment of non-small cell lung cancer complicated with EGFR gene mutation is similar to that of Gefitinib. In patients with advanced NSCLC and EGFR gene mutations, oxitinib treatment is associated with significantly longer PFS and lower adverse reaction rate compared with Gefitinib treatment.
-
To determine the effects of donor and red blood cells concentrate characteristics on recipient hemoglobin increment following red blood cells transfusion in pediatric patients. ⋯ Donors' age and Rh blood group and red blood cell concentrates' washing accounts for significant rise in recipient's post-transfusion hemoglobin. These factors may be used to predict changes in recipients' hemoglobin before transfusion.
-
To compare the success rates and safety of two-doses of methotrexate versus single dose of methotrexate in ectopic tubal pregnancy. ⋯ Although, β -hCG resolution time was significantly low in two-dose protocol but single-dose methotrexate offered comparable success rates versus two-dose protocol. Side effects were mild and comparable in both methotrexate treatment protocols. Methotrexate was found to be effective in the medical management of ectopic pregnancy.
-
To explore the effects of neoadjuvant chemotherapy combined with customized tumor-type total knee arthroplasty (TKA) on immune function and limb function in the treatment of malignant bone tumors around the knee joint. ⋯ Neoadjuvant chemotherapy combined with customized tumor-type TKA for knee malignant bone tumors is an excellent safety treatment for malignant bone tumors around the knee joint, boasting a variety of benefits, such as significantly ameliorating the immune function of patients and promoting the recovery of limb function, which is worthy of clinical application.